Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.
He co-led the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease and has chaired the UK Renal Trials Network since 2020.
He also aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease.
Objectives:
1) Understand the EMPA-KIDNEY trial results
2) Consider how EMPA-KIDNEY fits with the totality of the large-scale flozin trial evidence
3) Explore the absolute benefit and harms of flozins in different types of at risk groups
